NEW YORK, April 21 /PRNewswire-FirstCall/ -- Nephros, Inc. , a medical device company specializing in the treatment of end-stage renal disease, today announced that it has named Joleen C. Turner to be Vice President of Marketing and Business Development, effective today.
In this role, Ms. Turner, an experienced international marketing executive, will lead the development of Nephros’s marketing strategy, identifying new markets and channels, and applying the creative use of new media communications.
“I am pleased to welcome Joleen to the Nephros team,” Nephros CEO Norman J. Barta said. “Joleen’s experience and expertise solidify the company’s commercialization resources as Nephros pursues its goal of aggressively expanding product sales.”
Ms. Turner’s appointment comes as Nephros plans the launch of its OLpur(TM) H2H(TM) Hemodiafiltration Module and OLpur(TM) MD 220 Hemodiafilter products in the United States, subject to receiving the requisite regulatory approvals.
Ms. Turner has 20 years of international experience in strategic marketing, product development and product commercialization with high technology, professional service and life-science corporations. Since June 2006, she has been an independent consultant working with companies such as Boehringer Ingelheim, Pfizer, and Pepsico. She recently led the marketing and packaging launch of a leading respiratory combination drug with revenues now exceeding US $1 billion.
Previously Ms. Turner held the position of Director, Strategic Programs, for Aris Global, a leader in life-science safety and regulatory technology solutions, where her strategic marketing initiatives contributed to the company’s record growth and success in the regulatory and medical information markets. Ms. Turner has held several senior management positions in Western Europe, including: Accovion GmbH, a spin-off of Aventis Pharmaceuticals, where she was responsible for rebranding and strategic marketing programs that resulted in a continuous pipeline of clinical research business and revenue generation; and KiData AG, where she served as Vice President for Strategic Marketing and Business Development.
Ms. Turner received a B.S. degree in Health Sciences from California State University and MBA and Ph.D. degrees in Business Administration from Buxton University. She is also a candidate for an M.S. degree in marketing from Alfred Whitehead College of Redlands University.
About Nephros, Inc.
Nephros, Inc., headquartered in New York City, is a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system is designed to remove a range of harmful substances more effectively and more cost-effectively than existing ESRD treatment methods, particularly with respect to substances known collectively as “middle molecules.” These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros products are sold and distributed throughout Europe and are currently being used in over 50 clinics in Europe.
Nephros also markets a line of water filtration products, the Dual Stage Ultrafilter (DSU). Nephros’s patented dual stage cold sterilization Ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out viruses, parasites and other biological elements. The DSU’s proprietary dual-stage filtration design reduces the risk of filtration failure. With an initial focus on health care, the DSU is in a pilot-use program at a major U.S. medical center and has been selected for further development by the U.S. Marine Corps.
For more information on Nephros, please contact Nephros at 212-781-5113, and visit Nephros’s website, www.nephros.com.
Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements include statements regarding the efficacy and intended use of the Nephros’s technologies under development, the timelines for bringing such products to market and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. For such statements, Nephros claims the protection of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros’s control. Actual results may differ materially from the expectations contained in the forward- looking statements. Factors that may cause such differences include the risks that: (i) Nephros may not be able to obtain funding if and when needed or on terms favorable to it in order to continue operations or fund its clinical trials; (ii) Nephros may not be able to continue as a going concern; (iii) Nephros may not be able to liquidate its short-term investments when needed to fund its operations; (iv) Nephros may be unable to maintain compliance with the American Stock Exchange’s continued listing standards; (v) products that appeared promising to Nephros in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre- clinical or clinical trials; (vi) Nephros may not obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (vii) Nephros may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures; (viii) HDF therapy may not be accepted in the United States and/or Nephros’ technology and products may not be accepted in current or future target markets, which could lead to failure to achieve market penetration of Nephros’ products; (ix) Nephros may not be able to sell its ESRD therapy or water filtration products at competitive prices or profitably; (x) Nephros may not be able to secure or enforce adequate legal protection, including patent protection, for its products; and (xi) Nephros may not be able to achieve sales growth in Europe or expand into other key geographic markets. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros’ filings with the Securities and Exchange Commission, including Nephros’ Annual Report on Form 10-KSB filed with the SEC for the fiscal year ended December 31, 2007. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Nephros, Inc., +1-212-781-5113
Web site: http://www.nephros.com/
